SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it will report third quarter 2017 financial results on Thursday, November 2, 2017, after the financial markets close.
Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) on November 2, 2017, to discuss third quarter 2017 financial results and operational updates. A press release outlining the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 85402256. Interested parties may access the live teleconference in the Investors section of the company’s website at http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on November 2, 2017.
A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), Conference ID 85402256. The conference call will also be archived on the Fluidigm Investors page at http://investors.fluidigm.com/.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact:
Fluidigm Corporation
Ana Petrovic
Director, Corporate Development and Investor Relations
650 243 6628
[email protected]


Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



